Related Experiment Videos
Diagnosis of gastrointestinal stromal tumors: A consensus approach
Christopher D M Fletcher1, Jules J Berman, Christopher Corless
1Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston MA 02115, USA.
Abstract:
As a result of major recent advances in understanding the biology of gastrointestinal stromal tumors (GISTs), specifically recognition of the central role of activating KIT mutations and associated KIT protein expression in these lesions, and the development of novel and effective therapy for GISTs using the receptor tyrosine kinase inhibitor STI-571, these tumors have become the focus of considerable attention by pathologists, clinicians, and patients. Stromal/mesenchymal tumors of the gastrointestinal tract have long been a source of confusion and controversy with regard to classification, line(s) of differentiation, and prognostication. Characterization of the KIT pathway and its phenotypic implications has helped to resolve some but not all of these issues. Given the now critical role of accurate and reproducible pathologic diagnosis in ensuring appropriate treatment for patients with GIST, the National Institutes of Health convened a GIST workshop in April 2001 with the goal of developing a consensus approach to diagnosis and morphologic prognostication. Key elements of the consensus, as described herein, are the defining role of KIT immunopositivity in diagnosis and a proposed scheme for estimating metastatic risk in these lesions, based on tumor size and mitotic count, recognizing that it is probably unwise to use the definitive term "benign" for any GIST, at least at the present time.
Insights
Recent advances in gastrointestinal stromal tumors (GISTs) biology, particularly KIT mutations, have led to new therapies. A consensus approach for GIST diagnosis and prognostication, focusing on KIT immunopositivity and risk factors, is now established.
Area of Science:
- Gastrointestinal Pathology
- Oncology
- Molecular Diagnostics
Background:
- Gastrointestinal stromal tumors (GISTs) have historically presented diagnostic and classification challenges.
- Recent breakthroughs identified activating KIT mutations as central to GIST biology.
- The development of targeted therapy, like STI-571, has increased focus on GISTs.
Framework:
- A National Institutes of Health (NIH) workshop convened in April 2001 to establish diagnostic and prognostic consensus for GISTs.
- The consensus emphasizes the critical role of accurate pathologic diagnosis for effective patient treatment.
- Key diagnostic criteria include KIT immunopositivity.
Implementation:
- The consensus proposes a scheme for estimating metastatic risk based on tumor size and mitotic count.
- This approach aims to standardize GIST prognostication.
- The term "benign" is cautiously avoided for GISTs due to their unpredictable nature.
Implications:
- Standardized diagnostic and prognostic criteria improve patient management and treatment selection for GISTs.
- Understanding KIT pathway implications aids in resolving long-standing controversies in stromal tumor classification.
- This consensus provides a framework for future research and clinical practice in GIST management.